CLINICAL TRIALS PROFILE FOR LABETALOL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for labetalol hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00000291 ↗ | Effects of Labetalol on Human Cocaine Use - 8 | Completed | University of Minnesota | Phase 2 | 1997-10-01 | The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine. |
NCT00000291 ↗ | Effects of Labetalol on Human Cocaine Use - 8 | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 2 | 1997-10-01 | The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine. |
NCT00000291 ↗ | Effects of Labetalol on Human Cocaine Use - 8 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1997-10-01 | The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine. |
NCT00000297 ↗ | Effects of Labetalol on Nicotine Administration in Humans - 14 | Completed | University of Minnesota | Phase 2 | 1998-10-01 | The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine |
NCT00000297 ↗ | Effects of Labetalol on Nicotine Administration in Humans - 14 | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 2 | 1998-10-01 | The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine |
NCT00000297 ↗ | Effects of Labetalol on Nicotine Administration in Humans - 14 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1998-10-01 | The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine |
NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | US Department of Veterans Affairs | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for labetalol hydrochloride
Condition Name
Clinical Trial Locations for labetalol hydrochloride
Trials by Country
Clinical Trial Progress for labetalol hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for labetalol hydrochloride
Sponsor Name